Table 3.
Results of methodological quality.
| Study | Validity criteriaa met | Study qualityb | Quality measurement adherence |
|
| Randomized clinical trials | ||||
| Artinian [27] | Not applicablec | Low | Low | |
| Jan [28] | a, b, c, d, i, j | High | Low | |
| Chan [29] | a, b, f, i, j | Low | Low | |
| Chan [30] | a, b, c, f, hd, i, j | High | High | |
| Joseph [31] | a, b, c, d, e, h, i, j | High | Low | |
| Ross [32] | a, b, c, d, e, he, i, j, k | High | Low | |
| Guendelman [34] | a, b, d, i, j | Low | Low | |
| DeVito Dabbs [35] | a, b, c, e, i, j | High | Low | |
| Van der Meer [36] | a, b, c, i, j, k | High | Low | |
| Van der Meer [37] | a, c, hf, i, j, k | High | Low | |
| Prospective design/clinical trial or cohort design | ||||
| Cherry [33] | Low | Low | ||
| Dew [39] | Low | Low | ||
| Survey | ||||
| Dilorio [38] | Low | Low | ||
a a: randomization adequate; b: treatment allocation concealed; c: groups similar at baseline regarding most important indicators; d: patients blinded to intervention; e: care provider blinded to intervention; f: outcome assessor blinded to intervention; g: co-interventions avoided; h: compliance with intervention acceptable; i: dropout rate after baseline acceptable; j: outcome assessed similarly in all groups; k: intention-to-treat analysis included.
b That is, 6 of 11 validity criteria were met.
c No data on medication adherence for the control group and therefore judged as low quality.
d Compliance was acceptable in the first interval (<90 days).
e Compliance was acceptable in the first interval (6 months).
f Compliance was acceptable in the first interval (3 months).